Phase IIa study of TP300 in patients with advanced gastric cancer.

• Research type

  Research Study

• Full title

  A phase IIa, open-label, multi-centre study of TP300 as a single agent first line therapy in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.

• IRAS ID

  25892

• Contact name

  Thomas Ronald Jeffry Evans

• Contact email

  j.evans@beatson.gla.ac.uk

• Eudract number

  2009-012097-12

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  Research Summary not published at request of researcher

• REC name

  West of Scotland REC 1

• REC reference

  09/S0703/92

• Date of REC Opinion

  3 Sep 2009

• REC opinion

  Further Information Favourable Opinion